{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T23:06:07Z","timestamp":1775603167124,"version":"3.50.1"},"reference-count":101,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,6,28]],"date-time":"2025-06-28T00:00:00Z","timestamp":1751068800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,28]],"date-time":"2025-06-28T00:00:00Z","timestamp":1751068800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflammopharmacol"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s10787-025-01822-x","type":"journal-article","created":{"date-parts":[[2025,6,28]],"date-time":"2025-06-28T03:39:09Z","timestamp":1751081949000},"page":"3583-3595","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Protease activated receptor inhibitors in rheumatoid arthritis: a new frontier in treatment"],"prefix":"10.1007","volume":"33","author":[{"given":"Tayyaba","family":"Rana","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8636-8644","authenticated-orcid":false,"given":"Huma","family":"Hameed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2710-6000","authenticated-orcid":false,"given":"Ana Cl\u00e1udia","family":"Paiva-Santos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad","family":"Jamshaid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muneeba","family":"Anwar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,28]]},"reference":[{"key":"1822_CR1","first-page":"2694","volume":"6","author":"TA Addissouky","year":"2024","unstructured":"Addissouky TA, el Sayed I, Ali M (2024) Conservative and emerging rehabilitative approaches for knee osteoarthritis management. J Clin Orthop Trauma Care 6:2694\u20133248","journal-title":"J Clin Orthop Trauma Care"},{"key":"1822_CR2","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1016\/j.immuni.2022.11.009","volume":"55","author":"S Alivernini","year":"2022","unstructured":"Alivernini S, Firestein GS, McInnes IB (2022) The pathogenesis of rheumatoid arthritis. Immunity 55:2255\u20132270","journal-title":"Immunity"},{"key":"1822_CR3","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1007\/s00296-020-04731-0","volume":"41","author":"K Almutairi","year":"2021","unstructured":"Almutairi K, Nossent J, Preen D, Keen H, Inderjeeth C (2021) The global prevalence of rheumatoid arthritis: a meta-analysis based on a systematic review. Rheumatol Int 41:863\u2013877","journal-title":"Rheumatol Int"},{"key":"1822_CR4","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.3390\/biom10071002","volume":"10","author":"J Angelini","year":"2020","unstructured":"Angelini J, Talotta R, Roncato R, Fornasier G, Barbiero G, dal Cin L, Brancati S, Scaglione F (2020) JAK-inhibitors for the treatment of rheumatoid arthritis: a focus on the present and an outlook on the future. Biomolecules 10:1002","journal-title":"Biomolecules"},{"key":"1822_CR5","doi-asserted-by":"publisher","first-page":"117899","DOI":"10.1016\/j.bmc.2024.117899","volume":"112","author":"M Arfeen","year":"2024","unstructured":"Arfeen M, Srivastava A, Srivastava N, Khan RA, Al-Mahmoud SA, Mohammed HA (2024) Design, classification, and adverse effects of NSAIDs: a review on recent advancements. Bioorg Med Chem 112:117899. https:\/\/doi.org\/10.1016\/j.bmc.2024.117899","journal-title":"Bioorg Med Chem"},{"key":"1822_CR6","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/s41584-024-01109-5","volume":"20","author":"A Aubert","year":"2024","unstructured":"Aubert A, Jung K, Hiroyasu S, Pardo J, Granville DJ (2024) Granzyme serine proteases in inflammation and rheumatic diseases. Nat Rev Rheumatol 20:361\u2013376","journal-title":"Nat Rev Rheumatol"},{"key":"1822_CR7","doi-asserted-by":"publisher","first-page":"102022","DOI":"10.1016\/j.redox.2021.102022","volume":"44","author":"E Bang","year":"2021","unstructured":"Bang E, Kim DH, Chung HY (2021) Protease-activated receptor 2 induces ROS-mediated inflammation through Akt-mediated NF-\u03baB and FoxO6 modulation during skin photoaging. Redox Biol 44:102022","journal-title":"Redox Biol"},{"key":"1822_CR8","doi-asserted-by":"publisher","first-page":"101223","DOI":"10.1016\/j.nantod.2021.101223","volume":"39","author":"D Bhansali","year":"2021","unstructured":"Bhansali D, Teng SL, Lee CS, Schmidt BL, Bunnett NW, Leong KW (2021) Nanotechnology for pain management: current and future therapeutic interventions. Nano Today 39:101223","journal-title":"Nano Today"},{"key":"1822_CR9","doi-asserted-by":"publisher","first-page":"A43","DOI":"10.1161\/hyp.81.suppl_1.43","volume":"81","author":"R Bohovyk","year":"2024","unstructured":"Bohovyk R, Kravtsova O, Lowe M, Upadhyay G, Levchenko V, Halade G, Palygin O, Staruschenko A (2024) PAR1 inhibition with vorapaxar enhances renal function and modulates inflammation mediators in diabetic nephropathy. Hypertension 81:A43\u2013A43","journal-title":"Hypertension"},{"key":"1822_CR10","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1002\/9781119706687.ch50","volume-title":"Hoffbrand\u2019s Postgraduate Haematology","author":"WL Bor","year":"2025","unstructured":"Bor WL, Yin DRCP, Ten Berg JM, Baaten C, Ten Cate H (2025) Pathogenesis and management of arterial thrombosis. In Hoffbrand V, Moss PAH, Tuddenham EGD (Eds.), Hoffbrand\u2019s Postgraduate Haematology (8th ed., pp. 932\u2013946). Wiley Blackwell. https:\/\/doi.org\/10.1002\/9781119706687.ch50","edition":"8"},{"key":"1822_CR11","doi-asserted-by":"publisher","first-page":"970","DOI":"10.2174\/1389450120666181204164140","volume":"20","author":"BJ Buckley","year":"2019","unstructured":"Buckley BJ, Ali U, Kelso MJ, Ranson M (2019) The urokinase plasminogen activation system in rheumatoid arthritis: pathophysiological roles and prospective therapeutic targets. Curr Drug Targets 20:970\u2013981","journal-title":"Curr Drug Targets"},{"key":"1822_CR12","doi-asserted-by":"publisher","first-page":"2697","DOI":"10.1111\/febs.15829","volume":"288","author":"A Chandrabalan","year":"2021","unstructured":"Chandrabalan A, Ramachandran R (2021) Molecular mechanisms regulating proteinase-activated receptors (PARs). FEBS J 288:2697\u20132726","journal-title":"FEBS J"},{"key":"1822_CR13","doi-asserted-by":"publisher","first-page":"201","DOI":"10.3892\/etm.2024.12490","volume":"27","author":"B Chen","year":"2024","unstructured":"Chen B, Sun Y, Xu G, Jiang J, Zhang W, Wu C, Xue P, Cui Z (2024) Role of crosstalk between synovial cells and chondrocytes in osteoarthritis. Exp Ther Med 27:201","journal-title":"Exp Ther Med"},{"key":"1822_CR14","doi-asserted-by":"publisher","first-page":"53","DOI":"10.2147\/BTT.S260754","volume":"14","author":"MS Chimenti","year":"2020","unstructured":"Chimenti MS, D\u2019Antonio A, Conigliaro P, Ferrigno S, Vendola A, Ferraioli M, Triggianese P, Costa L, Caso F, Perricone R (2020) An update for the clinician on biologics for the treatment of psoriatic arthritis. Biologics: Targets Ther 14:53\u201375. https:\/\/doi.org\/10.2147\/BTT.S260754","journal-title":"Biologics: Targets Ther"},{"key":"1822_CR15","doi-asserted-by":"publisher","first-page":"758","DOI":"10.4103\/idoj.idoj_740_23","volume":"15","author":"R Choudhary","year":"2024","unstructured":"Choudhary R, Gupta V, Khandpur S (2024) Updates on the management of autoimmune bullous diseases. Indian Dermatol Online J 15:758\u2013769","journal-title":"Indian Dermatol Online J"},{"key":"1822_CR16","doi-asserted-by":"publisher","first-page":"102735","DOI":"10.1016\/j.autrev.2020.102735","volume":"20","author":"A Conforti","year":"2021","unstructured":"Conforti A, di Cola I, Pavlych V, Ruscitti P, Berardicurti O, Ursini F, Giacomelli R, Cipriani P (2021) Beyond the joints, the extra-articular manifestations in rheumatoid arthritis. Autoimmun Rev 20:102735","journal-title":"Autoimmun Rev"},{"key":"1822_CR17","first-page":"375","volume":"14","author":"J Dilleban","year":"2023","unstructured":"Dilleban J, Sundaresan T (2023) Role of non-steroidal anti-inflammatory drugs in orthopedics. Sys Rev Pharm 14:375\u2013379","journal-title":"Sys Rev Pharm"},{"key":"1822_CR18","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/s41392-023-01331-9","volume":"8","author":"Q Ding","year":"2023","unstructured":"Ding Q, Hu W, Wang R, Yang Q, Zhu M, Li M, Cai J, Rose P, Mao J, Zhu YZ (2023) Signaling pathways in rheumatoid arthritis: implications for targeted therapy. Signal Transduct Target Ther 8:68","journal-title":"Signal Transduct Target Ther"},{"key":"1822_CR19","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.bj.2020.06.010","volume":"44","author":"MI Edilova","year":"2021","unstructured":"Edilova MI, Akram A, Abdul-Sater AA (2021) Innate immunity drives pathogenesis of rheumatoid arthritis. Biomed J 44:172\u2013182","journal-title":"Biomed J"},{"key":"1822_CR20","doi-asserted-by":"publisher","unstructured":"Englund M, Turkiewicz A, Podsiadlo P, Mikecz K, Nigrovic PA, Raychaudhuri S, Thompson SD, Sparks JA, Chang S-C, Nguyen U-S, Losina E (2018) 70(1):40\u201348. https:\/\/doi.org\/10.1002\/art.40336","DOI":"10.1002\/art.40336"},{"key":"1822_CR21","doi-asserted-by":"publisher","first-page":"3830212","DOI":"10.1155\/2020\/3830212","volume":"2020","author":"Q Fang","year":"2020","unstructured":"Fang Q, Zhou C, Nandakumar KS (2020) Molecular and cellular pathways contributing to joint damage in rheumatoid arthritis. Mediators Inflamm 2020:3830212","journal-title":"Mediators Inflamm"},{"issue":"1","key":"1822_CR22","doi-asserted-by":"publisher","first-page":"C107","DOI":"10.1152\/ajpcell.00143.2025","volume":"329","author":"K Fedoriuk","year":"2025","unstructured":"Fedoriuk M, Stefanenko M, Bohovyk R, Semenikhina M, Lipschutz JH, Staruschenko A, Palygin O (2025) Serine proteases and protease-activated receptors signaling in the kidney. Am J Physiol-Cell Physiol 329(1):C107\u2013C117. https:\/\/doi.org\/10.1152\/ajpcell.00143.2025","journal-title":"Am J Physiol-Cell Physiol"},{"key":"1822_CR23","first-page":"591","volume":"18","author":"A Finckh","year":"2022","unstructured":"Finckh A, Gilbert B, Hodkinson B, Bae S-C, Thomas R, Deane KD, Alpizar-Rodriguez D, Lauper K (2022) Global epidemiology of rheumatoid arthritis. Nat Rev Rheumatol 18:591\u2013602","journal-title":"Nat Rev Rheumatol"},{"key":"1822_CR24","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/jth.14643","volume":"18","author":"OW Fox","year":"2020","unstructured":"Fox OW, Preston RJ (2020) Molecular basis of protease-activated receptor 1 signaling diversity. J Thromb Haemost 18:6\u201316","journal-title":"J Thromb Haemost"},{"key":"1822_CR25","doi-asserted-by":"publisher","first-page":"3517","DOI":"10.3390\/cells10123517","volume":"10","author":"J Friebel","year":"2021","unstructured":"Friebel J, Moritz E, Witkowski M, Jakobs K, Straessler E, D\u00f6rner A, Steffens D, Puccini M, Lammel S, Glauben R (2021) Pleiotropic effects of the protease-activated receptor 1 (PAR1) inhibitor, vorapaxar, on atherosclerosis and vascular inflammation. Cells 10:3517","journal-title":"Cells"},{"key":"1822_CR26","doi-asserted-by":"publisher","first-page":"102227","DOI":"10.1016\/j.coph.2022.102227","volume":"64","author":"CM Garcia-Gonzalez","year":"2022","unstructured":"Garcia-Gonzalez CM, Baker J (2022) Treatment of early rheumatoid arthritis: methotrexate and beyond. Curr Opin Pharmacol 64:102227","journal-title":"Curr Opin Pharmacol"},{"key":"1822_CR27","doi-asserted-by":"publisher","first-page":"e994","DOI":"10.52225\/narra.v4i3.994","volume":"4","author":"AR Ginting","year":"2024","unstructured":"Ginting AR, Munir D, Amin MM, Darlan DM, Putra A, Rusda M, Mutiara E, Mayasari E, Rozi MF (2024) Mesenchymal stem cells for immune modulation in systemic lupus erythematosus: from bench research to clinical applications. Narra J 4:e994\u2013e994","journal-title":"Narra J"},{"key":"1822_CR28","doi-asserted-by":"publisher","first-page":"57512","DOI":"10.12775\/JEHS.2025.78.57512","volume":"78","author":"M Gruszka","year":"2025","unstructured":"Gruszka M, Pola\u0144ska P, Kubicka M, Zakrocka M, Fick J (2025) Adverse effects of oral glucocorticoid therapy-a brief review of literature. J Educ Health Sport 78:57512\u201357512","journal-title":"J Educ Health Sport"},{"key":"1822_CR29","doi-asserted-by":"publisher","DOI":"10.1101\/2025.01.10.632345","author":"MK Ha","year":"2025","unstructured":"Ha MK, Deuren VV, de Carvalho Fraga CA, Hotterbeekx A, Dehoorne J, Renson T, Geens E, Aerts N, Heusdens C, Kuznetsova M, Mechelen MV (2025) Generation of a T cell receptor, cytokine and cell repertoire synovial fluid atlas to define commonalities and dissimilarities between arthritic diseases through systems immunology approaches. bioRxiv. https:\/\/doi.org\/10.1101\/2025.01.10.632345","journal-title":"bioRxiv"},{"key":"1822_CR30","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12964-025-02066-6","volume":"23","author":"A Habibi","year":"2025","unstructured":"Habibi A, Ruf W, Schurgers L (2025) Protease-activated receptors in vascular smooth muscle cells: a bridge between thrombo-inflammation and vascular remodelling. Cell Commun Signal 23:57","journal-title":"Cell Commun Signal"},{"issue":"6","key":"1822_CR31","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/j.ard.2025.03.002","volume":"84","author":"ML Hetland","year":"2025","unstructured":"Hetland ML, Heiberg MS, Sokka-Isler T, Rudin A, \u00d8stergaard M, Haavardsholm E, Rutanen J, van Vollenhoven R, Grondal G, \u00d8rnbjerg LM (2025) Treatment with methotrexate plus oral prednisolone versus triple therapy (methotrexate\/sulfasalazine\/hydroxychloroquine) plus intra-articular glucocorticoids in early rheumatoid arthritis: a prespecified nonrandomised subgroup analysis of clinical and radiographic data at 48 weeks from the NORD-STAR trial's conventional treatment arm. Ann Rheum Dis. 84(6):937\u2013948. https:\/\/doi.org\/10.1016\/j.ard.2025.03.002","journal-title":"Ann Rheum Dis"},{"key":"1822_CR32","doi-asserted-by":"publisher","first-page":"211","DOI":"10.5551\/jat.10.211","volume":"10","author":"K Hirano","year":"2003","unstructured":"Hirano K, Kanaide H (2003) Role of protease-activated receptors in the vascular system. J Atheroscler Thromb 10:211\u2013225","journal-title":"J Atheroscler Thromb"},{"key":"1822_CR33","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1016\/j.molcel.2022.02.021","volume":"82","author":"D Huang","year":"2022","unstructured":"Huang D, Kraus WL (2022) The expanding universe of PARP1-mediated molecular and therapeutic mechanisms. Mol Cell 82:2315\u20132334","journal-title":"Mol Cell"},{"key":"1822_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/mmr.2025.13467","volume":"31","author":"R Huo","year":"2025","unstructured":"Huo R, Wei C, Yang Y, Lin J, Huang X (2025) Hydroxychloroquine: a double-edged sword. Mol Med Rep 31:1\u201311","journal-title":"Mol Med Rep"},{"key":"1822_CR35","doi-asserted-by":"publisher","first-page":"1205062","DOI":"10.3389\/fphar.2023.1205062","volume":"14","author":"Z Jing-Lun","year":"2023","unstructured":"Jing-Lun Z, Shuang C, Li-Mei Z, Xiao-Dong L (2023) YKL-40 promotes chemokine expression following drug-induced liver injury via TF-PAR1 pathway in mice. Front Pharmacol 14:1205062","journal-title":"Front Pharmacol"},{"key":"1822_CR36","doi-asserted-by":"publisher","first-page":"101930","DOI":"10.1016\/j.berh.2024.101930","volume":"38","author":"AH Jonsson","year":"2024","unstructured":"Jonsson AH (2024) Granzyme K+ CD8 T cells in autoimmunity. Best Pract Res Clini Rheumatol 38:101930","journal-title":"Best Pract Res Clini Rheumatol"},{"key":"1822_CR37","doi-asserted-by":"publisher","first-page":"370","DOI":"10.3390\/ijms25010370","volume":"25","author":"SM Julovi","year":"2023","unstructured":"Julovi SM, McKelvey K, Minhas N, Chan Y-KA, Xue M, Jackson CJ (2023) Involvement of PAR-2 in the induction of cell-specific matrix metalloproteinase-2 by activated protein C in cutaneous wound healing. Int J Mol Sci 25:370","journal-title":"Int J Mol Sci"},{"key":"1822_CR38","doi-asserted-by":"publisher","first-page":"24285","DOI":"10.1038\/s41598-021-03346-0","volume":"11","author":"S Kalogera","year":"2021","unstructured":"Kalogera S, He Y, Bay-Jensen A-C, Gantzel T, Sun S, Manon-Jensen T, Karsdal MA, Thudium CS (2021) The activation fragment of PAR2 is elevated in serum from patients with rheumatoid arthritis and reduced in response to anti-IL6R treatment. Sci Rep 11:24285","journal-title":"Sci Rep"},{"key":"1822_CR39","doi-asserted-by":"publisher","first-page":"e21472","DOI":"10.1096\/fj.202001801R","volume":"35","author":"MK Kaneva","year":"2021","unstructured":"Kaneva MK, Muley MM, Krustev E, Reid AR, Souza PR, Dell\u2019Accio F, McDougall JJ, Perretti M (2021) Alpha-1-antitrypsin reduces inflammation and exerts chondroprotection in arthritis. FASEB J 35:e21472","journal-title":"FASEB J"},{"key":"1822_CR40","doi-asserted-by":"publisher","first-page":"63","DOI":"10.7150\/ijbs.12690","volume":"12","author":"Y Kanno","year":"2016","unstructured":"Kanno Y, Ishisaki A, Kawashita E, Kuretake H, Ikeda K, Matsuo O (2016) uPA attenuated LPS-induced inflammatory osteoclastogenesis through the plasmin\/PAR-1\/Ca2+\/CaMKK\/AMPK axis. Int J Biol Sci 12:63","journal-title":"Int J Biol Sci"},{"key":"1822_CR41","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1007\/s12015-020-09954-z","volume":"16","author":"A Karamini","year":"2020","unstructured":"Karamini A, Bakopoulou A, Andreadis D, Gkiouras K, Kritis A (2020) Therapeutic potential of mesenchymal stromal stem cells in rheumatoid arthritis: a systematic review of in vivo studies. Stem Cell Rev Rep 16:276\u2013287","journal-title":"Stem Cell Rev Rep"},{"key":"1822_CR42","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.3390\/jcm14062107","volume":"14","author":"P Kawczak","year":"2025","unstructured":"Kawczak P, Feszak IJ, B\u0105czek T (2025) Abatacept, golimumab, and sarilumab as selected bio-originator disease-modifying antirheumatic drugs with diverse mechanisms of action in their current use in treatment. J Clin Med 14:2107","journal-title":"J Clin Med"},{"key":"1822_CR43","doi-asserted-by":"publisher","first-page":"S195","DOI":"10.4103\/0972-6748.328861","volume":"30","author":"A Khan","year":"2021","unstructured":"Khan A, Pooja V, Chaudhury S, Bhatt V, Saldanha D (2021) Assessment of depression, anxiety, stress, and quality of life in rheumatoid arthritis patients and comparison with healthy individuals. Ind Psychiatry J 30:S195\u2013S200","journal-title":"Ind Psychiatry J"},{"key":"1822_CR44","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1080\/1354750X.2020.1794043","volume":"26","author":"B Kolarz","year":"2021","unstructured":"Kolarz B, Podgorska D, Podgorski R (2021) Insights of rheumatoid arthritis biomarkers. Biomarkers 26:185\u2013195","journal-title":"Biomarkers"},{"key":"1822_CR45","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/s41584-022-00793-5","volume":"18","author":"N Komatsu","year":"2022","unstructured":"Komatsu N, Takayanagi H (2022) Mechanisms of joint destruction in rheumatoid arthritis\u2014immune cell\u2013fibroblast\u2013bone interactions. Nat Rev Rheumatol 18:415\u2013429","journal-title":"Nat Rev Rheumatol"},{"key":"1822_CR46","doi-asserted-by":"publisher","first-page":"5629","DOI":"10.3390\/ijms20225629","volume":"20","author":"S Li","year":"2019","unstructured":"Li S, Tarlac V, Hamilton JR (2019) Using PAR4 inhibition as an anti-thrombotic approach: why, how, and when? Int J Mol Sci 20:5629","journal-title":"Int J Mol Sci"},{"key":"1822_CR47","doi-asserted-by":"publisher","first-page":"1520063","DOI":"10.3389\/fimmu.2025.1520063","volume":"16","author":"Z Liang","year":"2025","unstructured":"Liang Z, Xie H, Wu D (2025) Immune mediated inflammatory diseases: moving from targeted biologic therapy, stem cell therapy to targeted cell therapy. Front Immunol 16:1520063","journal-title":"Front Immunol"},{"key":"1822_CR48","doi-asserted-by":"publisher","first-page":"9352","DOI":"10.3390\/ijms22179352","volume":"22","author":"F Lucena","year":"2021","unstructured":"Lucena F, McDougall JJ (2021) Protease activated receptors and arthritis. Int J Mol Sci 22:9352","journal-title":"Int J Mol Sci"},{"key":"1822_CR49","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1007\/s12975-024-01233-0","volume":"16","author":"T Mavridis","year":"2025","unstructured":"Mavridis T, Choratta T, Papadopoulou A et al. (2025) Protease-activated receptors (PARs): biology and therapeutic potential in perioperative stroke. Transl Stroke Res. 16:933\u2013951. https:\/\/doi.org\/10.1007\/s12975-024-01233-0","journal-title":"Transl Stroke Res"},{"key":"1822_CR50","doi-asserted-by":"publisher","first-page":"116283","DOI":"10.1016\/j.bcp.2024.116283","volume":"228","author":"S Mazumder","year":"2024","unstructured":"Mazumder S, Bindu S, Debsharma S, Bandyopadhyay U (2024) Induction of mitochondrial toxicity by non-steroidal anti-inflammatory drugs (NSAIDs): the ultimate trade-off governing the therapeutic merits and demerits of these wonder drugs. Biochem Pharmacol 228:116283. https:\/\/doi.org\/10.1016\/j.bcp.2024.116283","journal-title":"Biochem Pharmacol"},{"key":"1822_CR51","doi-asserted-by":"publisher","first-page":"257","DOI":"10.3389\/fendo.2018.00257","volume":"9","author":"K McCulloch","year":"2018","unstructured":"McCulloch K, McGrath S, Huesa C, Dunning L, Litherland G, Crilly A, Hultin L, Ferrell WR, Lockhart JC, Goodyear CS (2018) Rheumatic disease: protease-activated receptor-2 in synovial joint pathobiology. Front Endocrinol 9:257","journal-title":"Front Endocrinol"},{"key":"1822_CR52","doi-asserted-by":"publisher","first-page":"174480692110161","DOI":"10.1177\/17448069211016141","volume":"17","author":"JJ McDougall","year":"2021","unstructured":"McDougall JJ, McConnell M, Reid AR (2021) Intracellular versus extracellular inhibition of calpain I causes differential effects on pain in a rat model of joint inflammation. Mol Pain 17:17448069211016140","journal-title":"Mol Pain"},{"key":"1822_CR53","unstructured":"Mignot S (2020) M\u00e9canismes de contr\u00f4le de l\u2019inflammation dans l\u2019arthropathie h\u00e9mophilique par les fibroblastes-like synoviocytes (FLS) et le FVIII. M\u00e9decine humaine et pathologie. Universit\u00e9 Paris Cit\u00e9. https:\/\/theses.hal.science\/tel-04202695\/"},{"key":"1822_CR54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4236\/ojra.2025.151001","volume":"15","author":"Y Mohammed","year":"2025","unstructured":"Mohammed Y, Rajak R (2025) Efficacy and safety of janus kinase inhibitors (JAKi) versus Interleukin 17 inhibitors (IL-17i) in the treatment of active non-radiographic axial spondyloarthritis (nr-ax SpA), a comparative systematized review. Open J Rheumatol Autoimmune Dis 15:1\u201321","journal-title":"Open J Rheumatol Autoimmune Dis"},{"key":"1822_CR55","doi-asserted-by":"publisher","first-page":"113126","DOI":"10.1016\/j.biopha.2022.113126","volume":"151","author":"RB Mrid","year":"2022","unstructured":"Mrid RB, Bouchmaa N, Ainani H, el Fatimy R, Malka G, Mazini L (2022) Anti-rheumatoid drugs advancements: new insights into the molecular treatment of rheumatoid arthritis. Biomed Pharmacother 151:113126","journal-title":"Biomed Pharmacother"},{"key":"1822_CR56","doi-asserted-by":"publisher","first-page":"3017","DOI":"10.3390\/cells10113017","volume":"10","author":"A-L M\u00fcller","year":"2021","unstructured":"M\u00fcller A-L, Payandeh Z, Mohammadkhani N, Mubarak S, Zakeri A, Alagheband Bahrami A, Brockm\u00fcller A, Shakibaei M (2021) Recent advances in understanding the pathogenesis of rheumatoid arthritis: new treatment strategies. Cells 10:3017","journal-title":"Cells"},{"key":"1822_CR57","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.jpain.2020.12.006","volume":"22","author":"J Mwirigi","year":"2021","unstructured":"Mwirigi J, Kume M, Hassler SN, Ahmad A, Ray PR, Jiang C, Chamessian A, Mseeh N, Ludwig BP, Rivera BD (2021) A role for protease activated receptor type 3 (PAR3) in nociception demonstrated through development of a novel peptide agonist. J Pain 22:692\u2013706","journal-title":"J Pain"},{"key":"1822_CR58","unstructured":"Narula VR (2022) Investigating the properties of synovial fluid extracellular vesicles from patients with knee osteoarthritis and with or without obesity. (Doctoral dissertation, University of Auckland). Retrieved from https:\/\/auckland.figshare.com\/ndownloader\/files\/37572298"},{"key":"1822_CR59","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1136\/annrheumdis-2020-218398","volume":"80","author":"P Nash","year":"2021","unstructured":"Nash P, Kerschbaumer A, D\u00f6rner T, Dougados M, Fleischmann RM, Geissler K, McInnes I, Pope JE, van der Heijde D, Stoffer-Marx M (2021) Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement. Ann Rheum Dis 80:71\u201387","journal-title":"Ann Rheum Dis"},{"key":"1822_CR60","doi-asserted-by":"publisher","first-page":"1127277","DOI":"10.3389\/fimmu.2023.1127277","volume":"14","author":"M Niu","year":"2023","unstructured":"Niu M, Zhao F, Chen R, Li P, Bi L (2023) The transient receptor potential channels in rheumatoid arthritis: Need to pay more attention. Front Immunol 14:1127277","journal-title":"Front Immunol"},{"key":"1822_CR61","doi-asserted-by":"publisher","first-page":"e0248866","DOI":"10.1371\/journal.pone.0248866","volume":"16","author":"MDG Paglia","year":"2021","unstructured":"Paglia MDG, Silva MT, Lopes LC, Barberato-Filho S, Mazzei LG, Abe FC, de C\u00e1ssia Bergamaschi C (2021) Use of corticoids and non-steroidal anti-inflammatories in the treatment of rheumatoid arthritis: systematic review and network meta-analysis. PLoS ONE 16:e0248866","journal-title":"PLoS ONE"},{"key":"1822_CR62","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1186\/s12891-024-07888-y","volume":"25","author":"R Patnaik","year":"2024","unstructured":"Patnaik R, Varghese R, Jannati S, Naidoo N, Banerjee Y (2024) Targeting PAR2-mediated inflammation in osteoarthritis: a comprehensive in vitro evaluation of oleocanthal\u2019s potential as a functional food intervention for chondrocyte protection and anti-inflammatory effects. BMC Musculoskelet Disord 25:769","journal-title":"BMC Musculoskelet Disord"},{"key":"1822_CR63","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.21037\/tcr-24-1027","volume":"14","author":"R Patnaik","year":"2025","unstructured":"Patnaik R, Varghese RL, Khan S, Huda B, Bhurka F, Amiri L, Banerjee Y (2025) Targeting PAR-2-driven inflammatory pathways in colorectal cancer: mechanistic insights from atorvastatin and rosuvastatin treatment in cell line models. Transl Cancer Res 14:1531","journal-title":"Transl Cancer Res"},{"key":"1822_CR64","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1152\/physrev.00044.2021","volume":"103","author":"CJ Peach","year":"2023","unstructured":"Peach CJ, Edgington-Mitchell LE, Bunnett NW, Schmidt BL (2023) Protease-activated receptors in health and disease. Physiol Rev 103:717\u2013785","journal-title":"Physiol Rev"},{"key":"1822_CR65","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.3390\/biom11111668","volume":"11","author":"E Pompili","year":"2021","unstructured":"Pompili E, de Franchis V, Giampietri C, Leone S, de Santis E, Fornai F, Fumagalli L, Fabrizi C (2021) Protease activated receptor 1 and its ligands as main regulators of the regeneration of peripheral nerves. Biomolecules 11:1668","journal-title":"Biomolecules"},{"key":"1822_CR66","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s11010-022-04492-3","volume":"478","author":"P Prasad","year":"2023","unstructured":"Prasad P, Verma S, Surbhi, Ganguly NK, Chaturvedi V, Mittal SA (2023) Rheumatoid arthritis: advances in treatment strategies. Mol Cell Biochem 478:69\u201388","journal-title":"Mol Cell Biochem"},{"key":"1822_CR67","doi-asserted-by":"publisher","first-page":"869","DOI":"10.3390\/ijms22020869","volume":"22","author":"R Price","year":"2021","unstructured":"Price R, Mercuri NB, Ledonne A (2021) Emerging roles of protease-activated receptors (PARs) in the modulation of synaptic transmission and plasticity. Int J Mol Sci 22:869","journal-title":"Int J Mol Sci"},{"key":"1822_CR68","doi-asserted-by":"publisher","first-page":"2857","DOI":"10.3390\/cells10112857","volume":"10","author":"A-F Radu","year":"2021","unstructured":"Radu A-F, Bungau SG (2021) Management of rheumatoid arthritis: an overview. Cells 10:2857","journal-title":"Cells"},{"key":"1822_CR69","doi-asserted-by":"publisher","first-page":"1541879","DOI":"10.3389\/fcvm.2025.1541879","volume":"12","author":"R Rajala","year":"2025","unstructured":"Rajala R, Griffin CT (2025) Endothelial protease-activated receptor 4: impotent or important? Front Cardiovasc Med 12:1541879","journal-title":"Front Cardiovasc Med"},{"key":"1822_CR70","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.3390\/ijms26052211","volume":"26","author":"N Rashidi","year":"2025","unstructured":"Rashidi N, Liu C, Guillot PV, Tamaddon M (2025) Isolation, characterization, and in vitro cell studies of plant-based exosome-like nanovesicles for treatment of early osteoarthritis. Int J Mol Sci 26:2211","journal-title":"Int J Mol Sci"},{"key":"1822_CR71","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1080\/14712598.2021.1889511","volume":"22","author":"AS Rathore","year":"2022","unstructured":"Rathore AS, Stevenson JG, Chhabra H, Maharana C (2022) The global landscape on interchangeability of biosimilars. Expert Opin Biol Ther 22:133\u2013148","journal-title":"Expert Opin Biol Ther"},{"key":"1822_CR72","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s41232-024-00338-1","volume":"44","author":"G Reches","year":"2024","unstructured":"Reches G, Piran R (2024) Par2-mediated responses in inflammation and regeneration: choosing between repair and damage. Inflamm Regen 44:26","journal-title":"Inflamm Regen"},{"key":"1822_CR73","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1080\/17474086.2024.2438237","volume":"18","author":"EC Rodriguez-Merchan","year":"2025","unstructured":"Rodriguez-Merchan EC, De la Corte-Rodriguez H (2025) NSAIDS\/COXIBS for the treatment of musculoskeletal pain secondary to hemophilic arthropathy. Expert Rev Hematol 18:33\u201338","journal-title":"Expert Rev Hematol"},{"key":"1822_CR74","doi-asserted-by":"publisher","first-page":"169","DOI":"10.5114\/reum.2021.107026","volume":"59","author":"A Saki","year":"2021","unstructured":"Saki A, Rajaei E, Rahim F (2021) Safety and efficacy of tocilizumab for rheumatoid arthritis: a systematic review and metaanalysis of clinical trial studies. Reumatologia\/rheumatology 59:169\u2013179","journal-title":"Reumatologia\/rheumatology"},{"key":"1822_CR75","doi-asserted-by":"publisher","first-page":"101113","DOI":"10.1016\/j.bonr.2021.101113","volume":"15","author":"R Sanaei","year":"2021","unstructured":"Sanaei R, Kularathna P, Taghavi N, Hooper J, Pagel C, Mackie E (2021) Protease-activated receptor-2 promotes osteogenesis in skeletal mesenchymal stem cells at the expense of adipogenesis: involvement of interleukin-6. Bone Reports 15:101113","journal-title":"Bone Reports"},{"key":"1822_CR76","doi-asserted-by":"publisher","first-page":"1339337","DOI":"10.3389\/fimmu.2023.1339337","volume":"14","author":"JL Sanz-Cabanillas","year":"2024","unstructured":"Sanz-Cabanillas JL, G\u00f3mez-Garc\u00eda F, Gomez-Arias PJ, Montilla-L\u00f3pez A, Gay-Mimbrera J, Ruano J, Isla-Tejera B, Parra-Peralbo E (2024) Efficacy and safety of anakinra and canakinumab in PSTPIP1-associated inflammatory diseases: a comprehensive scoping review. Front Immunol 14:1339337","journal-title":"Front Immunol"},{"key":"1822_CR77","doi-asserted-by":"publisher","first-page":"e002960","DOI":"10.1136\/bmjresp-2024-002960","volume":"12","author":"S Sarkar","year":"2025","unstructured":"Sarkar S, Han JX, Azzopardi K, Dhar P, Saeed MA, Day S, Ranganathan S, Sutton P (2025) Protease-activated receptor 1 in the pathogenesis of cystic fibrosis. BMJ Open Respir Res 12:e002960. https:\/\/doi.org\/10.1136\/bmjresp-2024-002960","journal-title":"BMJ Open Respir Res"},{"key":"1822_CR78","doi-asserted-by":"publisher","first-page":"680043","DOI":"10.3389\/fphar.2021.680043","volume":"12","author":"S Shams","year":"2021","unstructured":"Shams S, Martinez JM, Dawson JR, Flores J, Gabriel M, Garcia G, Guevara A, Murray K, Pacifici N, Vargas MV (2021) The therapeutic landscape of rheumatoid arthritis: current state and future directions. Front Pharmacol 12:680043","journal-title":"Front Pharmacol"},{"key":"1822_CR79","doi-asserted-by":"publisher","first-page":"4687","DOI":"10.1007\/s11033-023-08406-4","volume":"50","author":"A Sharma","year":"2023","unstructured":"Sharma A, Goel A (2023) Pathogenesis of rheumatoid arthritis and its treatment with anti-inflammatory natural products. Mol Biol Rep 50:4687\u20134706","journal-title":"Mol Biol Rep"},{"key":"1822_CR80","doi-asserted-by":"publisher","first-page":"700","DOI":"10.3390\/ijms24010700","volume":"24","author":"E Spekker","year":"2022","unstructured":"Spekker E, K\u00f6rt\u00e9si T, V\u00e9csei L (2022) TRP channels: recent development in translational research and potential therapeutic targets in migraine. Int J Mol Sci 24:700","journal-title":"Int J Mol Sci"},{"key":"1822_CR81","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/s41568-021-00436-z","volume":"22","author":"S Srinivasan","year":"2022","unstructured":"Srinivasan S, Kryza T, Batra J, Clements J (2022) Remodelling of the tumour microenvironment by the kallikrein-related peptidases. Nat Rev Cancer 22:223\u2013238","journal-title":"Nat Rev Cancer"},{"key":"1822_CR82","first-page":"S233","volume":"24","author":"S Stone","year":"2021","unstructured":"Stone S, Malanga GA, Capella T (2021) Corticosteroids: review of the history, the effectiveness, and adverse effects in the treatment of joint pain. Pain Physician 24:S233","journal-title":"Pain Physician"},{"key":"1822_CR83","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/s41573-021-00259-5","volume":"21","author":"RJ Sullivan","year":"2022","unstructured":"Sullivan RJ, Weber JS (2022) Immune-related toxicities of checkpoint inhibitors: mechanisms and mitigation strategies. Nat Rev Drug Discovery 21:495\u2013508","journal-title":"Nat Rev Drug Discovery"},{"key":"1822_CR84","first-page":"1","volume":"8","author":"B Taghizadeh","year":"2024","unstructured":"Taghizadeh B (2024) Investigating Therapeutic Potential of Targeting Platelets in Cancer Treatment: A Literature Review. Undergrad Res Nat Clin Sci Technol J 8:1\u201314","journal-title":"Undergrad Res Nat Clin Sci Technol J"},{"key":"1822_CR85","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.freeradbiomed.2020.12.437","volume":"164","author":"J Torn\u00edn","year":"2021","unstructured":"Torn\u00edn J, Villasante A, Sol\u00e9-Mart\u00ed X, Ginebra M-P, Canal C (2021) Osteosarcoma tissue-engineered model challenges oxidative stress therapy revealing promoted cancer stem cell properties. Free Radical Biol Med 164:107\u2013118","journal-title":"Free Radical Biol Med"},{"key":"1822_CR86","doi-asserted-by":"publisher","first-page":"376","DOI":"10.3390\/compounds4020023","volume":"4","author":"A Tsoupras","year":"2024","unstructured":"Tsoupras A, Pafli S, Stylianoudakis C, Ladomenou K, Demopoulos CA, Philippopoulos A (2024) Anti-inflammatory and antithrombotic potential of metal-based complexes and porphyrins. Compounds 4:376\u2013400","journal-title":"Compounds"},{"key":"1822_CR87","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1097\/MCA.0000000000000409","volume":"27","author":"L Ungar","year":"2016","unstructured":"Ungar L, Rodriguez F, Mahaffey KW (2016) Vorapaxar: emerging evidence and clinical questions in a new era of PAR-1 inhibition. Coron Artery Dis 27:604\u2013615","journal-title":"Coron Artery Dis"},{"key":"1822_CR88","doi-asserted-by":"publisher","first-page":"102830","DOI":"10.1016\/j.autrev.2021.102830","volume":"20","author":"EF Vicente-Rabaneda","year":"2021","unstructured":"Vicente-Rabaneda EF, Atienza-Mateo B, Blanco R, Cavagna L, Ancochea J, Castaneda S, Gonzalez-Gay MA (2021) Efficacy and safety of abatacept in interstitial lung disease of rheumatoid arthritis: a systematic literature review. Autoimmun Rev 20:102830","journal-title":"Autoimmun Rev"},{"key":"1822_CR89","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.3390\/antiox11061153","volume":"11","author":"X Wang","year":"2022","unstructured":"Wang X, Fan D, Cao X, Ye Q, Wang Q, Zhang M, Xiao C (2022) The role of reactive oxygen species in the rheumatoid arthritis-associated synovial microenvironment. Antioxidants 11:1153","journal-title":"Antioxidants"},{"key":"1822_CR90","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1007\/s10067-024-07084-2","volume":"43","author":"X Wang","year":"2024","unstructured":"Wang X, Yang J, Yu L-Y, Zhang J, Zhang X, Shen H-L (2024) Effect of disease duration on the use of tofacitinib: a real-world study in elderly patients with rheumatoid arthritis. Clin Rheumatol 43:2807\u20132815","journal-title":"Clin Rheumatol"},{"key":"1822_CR91","doi-asserted-by":"publisher","first-page":"0102","DOI":"10.34133\/bmef.0102","volume":"6","author":"Q Wang","year":"2025","unstructured":"Wang Q, Ji J, Huang D, Gao C (2025) Biomaterials for modulating the immune microenvironment in rheumatoid arthritis. BME Front 6:0102","journal-title":"BME Front"},{"issue":"1","key":"1822_CR92","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1016\/j.joca.2024.06.011","volume":"32","author":"SN Wijesinghe","year":"2024","unstructured":"Wijesinghe SN, Ditchfield C, Flynn S, Agrawal J, Davis ET, Dajas-Bailador F, Chapman V, Jones SW (2024) Immunomodulation and fibroblast dynamics driving nociceptive joint pain within inflammatory synovium: unravelling mechanisms for therapeutic advancements in osteoarthritis. Osteoarthritis Cartilage 32(11):1358\u20131370. https:\/\/doi.org\/10.1016\/j.joca.2024.06.011","journal-title":"Osteoarthritis Cartilage"},{"key":"1822_CR93","doi-asserted-by":"publisher","first-page":"584116","DOI":"10.3389\/fimmu.2020.584116","volume":"11","author":"HL Wright","year":"2021","unstructured":"Wright HL, Lyon M, Chapman EA, Moots RJ, Edwards SW (2021) Rheumatoid arthritis synovial fluid neutrophils drive inflammation through production of chemokines, reactive oxygen species, and neutrophil extracellular traps. Front Immunol 11:584116","journal-title":"Front Immunol"},{"key":"1822_CR94","doi-asserted-by":"publisher","first-page":"2990","DOI":"10.1093\/rheumatology\/keaa701","volume":"60","author":"M Xue","year":"2021","unstructured":"Xue M, Lin H, Liang HPH, McKelvey K, Zhao R, March L, Jackson C (2021) Deficiency of protease-activated receptor (PAR) 1 and PAR2 exacerbates collagen-induced arthritis in mice via differing mechanisms. Rheumatol 60:2990\u20133003","journal-title":"Rheumatol"},{"key":"1822_CR95","doi-asserted-by":"publisher","first-page":"BSR20192620","DOI":"10.1042\/BSR20192620","volume":"40","author":"S Yan","year":"2020","unstructured":"Yan S, Ding H, Peng J, Wang X, Pang C, Wei J, Wei J, Chen H (2020) Down-regulation of protease-activated receptor 2 ameliorated osteoarthritis in rats through regulation of MAPK\/NF-\u03baB signaling pathway in vivo and in vitro. Biosci Rep 40:BSR20192620","journal-title":"Biosci Rep"},{"key":"1822_CR96","doi-asserted-by":"publisher","first-page":"175972025131471","DOI":"10.1177\/1759720X251314712","volume":"17","author":"J Yang","year":"2025","unstructured":"Yang J, Park Y, Lee JJ, Kwok S-K, Ju JH, Kim W-U, Park S-H (2025) Impact of glucocorticoids on the therapeutic efficacy of denosumab against osteoporosis in patients with rheumatoid arthritis. Ther Adv Musculoskelet Dis 17:1759720251314712","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"1822_CR97","doi-asserted-by":"publisher","DOI":"10.1055\/a-2569-6439","author":"J Yuan","year":"2025","unstructured":"Yuan J, Zhou S, Wu X, Li F, Lai Z, Ding Q, Wu W, Wang X, Dai J, Hu X, Lu Y (2025) Asn384Ser mutation in protein C is associated with multiple-site thrombosis in a young heterozygous male. Thromb Haemost. https:\/\/doi.org\/10.1055\/a-2569-6439","journal-title":"Thromb Haemost"},{"key":"1822_CR98","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1007\/s10787-025-01644-x","volume":"33","author":"I Zahoor","year":"2025","unstructured":"Zahoor I, Bala R, Wani SN, Chauhan S, Madaan R, Kumar R, Hakeem KR, Malik IA (2025) Potential role of NSAIDs loaded nano-formulations to treat inflammatory diseases. Inflammopharmacol 33:1189\u20131207 (2025). https:\/\/doi.org\/10.1007\/s10787-025-01644-x","journal-title":"Inflammopharmacol"},{"key":"1822_CR99","doi-asserted-by":"publisher","first-page":"1137918","DOI":"10.3389\/fimmu.2023.1137918","volume":"14","author":"Y Zheng","year":"2023","unstructured":"Zheng Y, Zhao J, Shan Y, Guo S, Schrodi SJ, He D (2023) Role of the granzyme family in rheumatoid arthritis: Current Insights and future perspectives. Front Immunol 14:1137918","journal-title":"Front Immunol"},{"key":"1822_CR100","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41413-024-00370-4","volume":"12","author":"R Zhou","year":"2024","unstructured":"Zhou R, Hu W, Ma PX, Liu C-J (2024) Versatility of 14-3-3 proteins and their roles in bone and joint-related diseases. Bone Res 12:58","journal-title":"Bone Res"},{"key":"1822_CR101","doi-asserted-by":"publisher","first-page":"4000","DOI":"10.1111\/febs.16406","volume":"289","author":"X Zhuo","year":"2022","unstructured":"Zhuo X, Wu Y, Fu X, Liang X, Xiang Y, Li J, Mao C, Jiang Y (2022) The Yin-Yang roles of protease-activated receptors in inflammatory signalling and diseases. FEBS J 289:4000\u20134020","journal-title":"FEBS J"}],"container-title":["Inflammopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-025-01822-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10787-025-01822-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-025-01822-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T01:32:53Z","timestamp":1757208773000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10787-025-01822-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,28]]},"references-count":101,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["1822"],"URL":"https:\/\/doi.org\/10.1007\/s10787-025-01822-x","relation":{},"ISSN":["0925-4692","1568-5608"],"issn-type":[{"value":"0925-4692","type":"print"},{"value":"1568-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,28]]},"assertion":[{"value":"24 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}